The program is one of three under the research collaboration and exclusive worldwide license agreement between TRexBio and Lilly, which leverages TRexBio's proprietary Deep Biology platform to identify and develop novel therapies for the treatment of immune-mediated diseases. Pursuant to the agreement, TRexBio has earned a double-digit million dollar milestone payment and is eligible to receive more than
'We are excited by the potential of TRB-051 to bring durable clinical benefit to patients in need of new therapies to treat dysregulation of the immune system,' said
'Given Lilly's status as a global industry leader, we view this milestone as further validation of the power of our Deep Biology Platform,' said
TRexBio's proprietary Deep Biology Platform was also integral in the identification and advancement of TRexBio's wholly-owned lead program, TRB-061, an agonist targeting TNF receptor 2 (TNFR2) designed to augment Tregs at the site of inflammation. TRB-061 is currently in IND enabling studies, and the company anticipates advancing the program into the clinic in the first half of 2025.
About TRexBio
TRexBio is a biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for immune-mediated diseases. Our powerful Deep Biology platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. TRexBio was founded and seed funded by
Contact:
Email: info@trex.bio
Tel: +1-858-344-8091
Email: jessica@litldog.com
(C) 2024 Electronic News Publishing, source